Case Report of Mesorectal Failure in the Treatment of Prostate Adenocarcinoma

Main Article Content

James L Shen, PhD John G Roubil, MD Linda Ding, PhD Julie Trifone, CMD Carla Bradford, PhD Fenghong Liu, PhD Yankhua Fan, PhD I-Lin Kuo, PhD Camelia Bunaciu, MS Salvatore Larosa, MS Suhong Yu, PhD Abdulnasser Khalifeh, PhD Jonathan Saleeby, MS Harry Bushe, MS Maryann Bishop-Jodoin, MEd Thomas J. FitzGerald, MD

Abstract

Prostate cancer afflicts a substantial portion of the male population with increasing incidence each decade after the age of 40. Standard of care for localized disease at presentation includes prostatectomy and/or radiation therapy which can include management of pelvic lymph nodes. However, the selection of lymph nodes treated by radiotherapy remains variable among practitioners including individual practitioners in the same institution. We present a patient with prostate adenocarcinoma who underwent radical prostatectomy with adjuvant radiotherapy for lymph node involvement and developed mesorectal failure secondary to metastatic spread to untreated tissue.

Keywords: Prostate cancer, Radiation therapy, Mesorectal

Article Details

How to Cite
SHEN, James L et al. Case Report of Mesorectal Failure in the Treatment of Prostate Adenocarcinoma. Medical Research Archives, [S.l.], v. 10, n. 11, nov. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3266>. Date accessed: 17 june 2024. doi: https://doi.org/10.18103/mra.v10i11.3266.
Section
Case Reports

References

1. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2016. National Cancer Institute. https://seer.cancer.gov/csr/1975_2016/, 2019.
2. Bekelman JE, Rumble RB, Chen RC, et al. Clinically localized prostate cancer: ASCO Clinical Practice Guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol. 2018;36(32):3251-3258.
3. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part I: Risk stratification, shared decision making, and care options. J Urol. 2018;199(3):683-690.
4. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended approaches and details of specific care options. J Urol. 2018;199(4):990-997.
5. Li G, Li Y, Wang J, et al. Guidelines for radiotherapy of prostate cancer (2020 edition). Precision Radiation Oncology. 2021;5(3):160-182.
6. Rogowski P, Roach M, Schmidt-Hegemann NS, et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021:16:50.
7. Nicosia L, Franzese C, Mazzola R, et al. Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. Strahlenther Onkol. 2020;196(3):213-221.
8. Soldatov A, von Klot CAJ, Walacides D, et al. Patterns of progression after 68Ga-PSMA-Ligand PET/CT-guided radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys. 2019;103(1):95-104.
9. Tran S, Jorcano S, Falco T, Lamanna G, Miralbell R, Zilli T. Oligorecurrent nodal prostate cancer: Long-term results of an elective nodal irradiation approach. Am J Clin Oncol. 2018;41(10):960-962.

Most read articles by the same author(s)